Everolimus for Estrogen Receptor-negative Breast Cancer Prevention: A Journey Begun?

Tamoxifen, the prototypic medication for breast cancer prevention, was approved for this purpose by the FDA in 1998. Other drugs have been proven to be effective in the ensuing decades. But the two major limitations of these have become clear over time: a lack of protection against hormone receptor-...

Full description

Saved in:
Bibliographic Details
Published inCancer prevention research (Philadelphia, Pa.) Vol. 15; no. 12; pp. 787 - 789
Main Authors Nye, Lauren, Khan, Seema A
Format Journal Article
LanguageEnglish
Published United States 01.12.2022
Subjects
Everolimus - therapeutic use
Female
Humans
Phosphatidylinositol 3-Kinases
Receptors, Estrogen
TOR Serine-Threonine Kinases
Triple Negative Breast Neoplasms
Online AccessGet full text

Cover

More Information
Summary:Tamoxifen, the prototypic medication for breast cancer prevention, was approved for this purpose by the FDA in 1998. Other drugs have been proven to be effective in the ensuing decades. But the two major limitations of these have become clear over time: a lack of protection against hormone receptor-negative breast cancer, and a profile of safety and tolerability that is unacceptable to the majority of women at increased breast cancer risk. Recent preclinical data on targeting of the key oncogenic pathway of PI3K/AKT/mTOR signaling with drugs such as rapamycin and everolimus are provocative. Their efficacy signal should be pursued with further research, but their safety and tolerability profiles remain a concern. See related article by Mazumdar et al., p. 791.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Editorial-2
ObjectType-Commentary-1
ISSN:1940-6207
1940-6215
DOI:10.1158/1940-6207.CAPR-22-0419